Wed, May 7, 8:12 PM (4 days ago)
### Summary of Revolution Medicines, Inc. (RVMD) Q1 2025 Financial Performance **Quarterly Financial Health:** - **Revenue:** $0. - **Net Loss:** $213.4 million, an increase of $97.4 million from Q1 2024. - **Cash and Cash Equivalents:** $337.3 million, a decrease of $209.5 million from Q1 2024. - **Cash Used in Operating Activities:** $194.4 million, an increase of $33.9 million from Q1 2024. **Performance Metrics:** - **Research and Development (R&D) Expenses:** $205.7 million, an increase of $87.7 million from Q1 2024. - **Daraxonrasib (RMC-6236):** $67.5 million. - **Zoldonrasib (RMC-9805):** $24.5 million. - **Elironrasib (RMC-6291):** $19.0 million. - **RAS Companion Inhibitors:** $0.4 million. - **Preclinical Programs:** $21.4 million. - **General and Administrative (G&A) Expenses:** $35.0 million, an increase of $12.2 million from Q1 2024. **Profit Margins:** - **Operating Margin:** -100%. - **Net Margin:** -100%. **Cash Flow:** - **Operating Cash Flow:** -$194.4 million. - **Investing Cash Flow:** -$15.9 million. - **Financing Cash Flow:** $0.9 million. **Earnings Changes:** - **Net Loss per Share:** -$1.13, an increase of $0.43 from Q1 2024. **Quarterly Performance Discussion:** - **R&D Focus:** Continued investment in clinical and preclinical programs. - **Cash Position:** Significant decrease in cash due to increased operating expenses. - **Operational Impact:** Increased headcount and clinical trial expenses. **Trends:** - **Increasing R&D and G&A Expenses:** Reflects ongoing clinical trials and operational scaling. - **Cash Burn:** High cash usage indicates significant investment in development activities. **Uncertainties:** - **Clinical Trial Outcomes:** Success of ongoing and planned clinical trials. - **Regulatory Approvals:** Timely and successful regulatory approvals for product candidates. - **Market Competition:** Competitive landscape and potential market entry of similar products. **Future Operations Impact:** - **Continued Investment:** High R&D and G&A expenses expected to continue. - **Cash Management:** Need for additional financing to sustain operations and development activities.